Phio Pharmaceuticals appoints Robert Bitterman as President and CEO effective Feb 20, 2023

Phio Pharmaceuticals Corp.

Bitterman, previously interim CEO since Sep 2022, appointed permanent President and CEO and remains Chair of the Board.
Employment agreement provides $440,000 base salary, up to 40% annual bonus, and 11,000 RSUs vesting over 2 years.
Bitterman has prior CEO experience at Cutanea Life Sciences and Isolagen; Board conducted a search before appointment.
He will continue as principal executive and financial officer; no family relationships or reportable transactions disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert J. Bitterman

President and Chief Executive Officer and Chair of the Board

PHIO · Phio Pharmaceuticals Corp.

Effective: 2023-02-20
Filed: February 22, 2023, 6:59 PM ET

On February 17, 2023, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert J. Bitterman, acting Executive Chairman of the Board and acting Interim Chief Executive Officer, to serve as the Company’s President and Chief Executive Officer and Chair of the Board, effective as of February 20, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert J. Bitterman was appointed as President and Chief Executive Officer and Chair of the Board at Phio Pharmaceuticals Corp..

Action: appointed
Role: President and Chief Executive Officer and Chair of the Board

Exact text from the filing

On February 17, 2023, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert J. Bitterman, acting Executive Chairman of the Board and acting Interim Chief Executive Officer, to serve as the Company’s President and Chief Executive Officer and Chair of the Board, effective as of February 20, 2023.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-23-001075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.